http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Simulations Plus Enters New Collaboration to Enhance Machine Learning Models for Ionization Constants (pKa)
-
Simulations Plus Presented New Scientific Developments at PAGE 2022
-
Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit International Organization for Childhood Cancer
-
Simulations Plus Realizes Early Success with its Concierge Program
-
Simulations Plus Reports Third Quarter Fiscal 2022 Financial Results
-
Simulations Plus Hosts 2nd Annual Pharmacometrics Workshop
-
Simulations Plus Collaborates with Multinational Pharmaceutical Company to Provide Modeling & Simulation Support for COVID-19 Treatment
-
Simulations Plus Sets Date for Third Quarter Fiscal Year 2022 Earnings Release and Conference Call
-
DILIsym Software Publication Outlines Impact on the CGRP Field for Migraine
-
Simulations Plus Releases ADMET Predictor Version 10.4 (X.4)
-
Simulations Plus (SLP) U.S. FDA Renews Annual DILIsym Software Licenses for 2022
-
U.S. FDA Renews Annual DILIsym Software Licenses for 2022
-
Simulations Plus (SLP) Successfully Delivers FDA-Funded Project
-
Simulations Plus Successfully Delivers FDA-Funded Project
-
Simulations Plus Enters New Collaboration to Advance DDDPlus™ Software
-
Simulations Plus to Present at the Berenberg Discover AI Seminar
-
Simulations Plus Reports Second Quarter Fiscal 2022 Financial Results
-
Simulations Plus (SLP) Announces $1.7M Grant for BIOLOGXsym
-
Simulations Plus Receives $1.7 Million Grant for BIOLOGXsym™ Macromolecule Safety Software
-
Simulations Plus Hosts the 2022 Model-Informed Drug Development (MIDD+) Scientific Conference
-
Simulations Plus Sets Date for Second Quarter Fiscal Year 2022 Earnings Release and Conference Call
-
Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit National Organization for Rare Disorders
-
Simulations Plus Releases MembranePlus 3.0
-
Simulations Plus to Present at Oppenheimer Annual Healthcare Conference
-
Simulations Plus to Present at Raymond James Institutional Investors Conference
-
Simulations Plus to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
-
Simulations Plus (SLP) Partners with Large Pharmaceutical Company to Drive Advancements to the GastroPlus Mechanistic Oral Absorption Model
-
Simulations Plus Partners with Large Pharmaceutical Company to Drive Advancements to the GastroPlus Mechanistic Oral Absorption Model
-
Simulations Plus Enters New Collaboration with Leading Animal Health Company
-
Simulations Plus to Present at Sidoti Winter Small Cap Investor Conference
-
Simulations Plus (SLP) Reports Q1 Revenues of $12.4M, Diluted EPS of $0.15
-
Simulations Plus Reports First Quarter Fiscal 2022 Financial Results
-
Lixoft Adds New Bioequivalence Module in MonolixSuite® Version 2021R1
-
Simulations Plus Sets Date for First Quarter Fiscal Year 2022 Earnings Release and Conference Call
-
Simulations Plus Extends its Distributor Agreement in Japan with Northern Science Consulting for Monolix™
-
Simulations Plus celebrates 25-year anniversary with $25,000 gift to nonprofit Dispensary of Hope
-
Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit, Dispensary of Hope
-
Simulations Plus Names Sharlene Evans to Board of Directors
-
Simulations Plus (SLP) Presented Breakthrough Scientific Data at Top Liver Disease Conference
-
Simulations Plus Presented Breakthrough Scientific Data at Top Liver Disease Conference
-
Simulations Plus Releases RENAsym® Version 1A Software for Kidney Injury
-
Simulations Plus Releases GastroPlus® Version 9.8.2
-
Simulations Plus (SLP) and University of Connecticut Announce FDA Contract to Accelerate Development of Long-Acting Injectable Products
-
Simulations Plus and the University of Connecticut Awarded New FDA Contract to Accelerate the Development of Long-Acting Injectable Products
-
Simulations Plus Reports Fourth Quarter and Full Year Fiscal 2021 Results
-
Simulations Plus Announces the University+ Program
-
Simulations Plus Announces Cash Dividend
-
Simulations Plus Sets Date for 4th Quarter and Fiscal Year 2021 Earnings Release and Conference Call
-
Simulations Plus (SLP) Announces 250k/year Grant from FDA
-
Simulations Plus Receives New Grant Award From the FDA

